Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – X-ray contrast imaging agent
Reexamination Certificate
2008-06-18
2010-10-12
Audet, Maury (Department: 1654)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
X-ray contrast imaging agent
C514S002600, C424S001690
Reexamination Certificate
active
07811551
ABSTRACT:
The invention relates to compounds of formula (I): and their use as targeting vectors that bind to receptors associated with angiogenesis. Such compounds may thus be used for diagnosis or therapy of, for example, malignant diseases, heart diseases, endometriosis, inflammation-related diseases, rheumatoid arthritis and Kaposi's sarcoma.
REFERENCES:
patent: 5888474 (1999-03-01), Lister-James
patent: 95/14714 (1995-06-01), None
patent: 01/77145 (2001-10-01), None
patent: 02/20610 (2002-03-01), None
patent: 02/062819 (2002-08-01), None
patent: 03/006491 (2003-01-01), None
Int'l Search Report dated Nov. 2004 for PCT/GB2004/003150.
Pearson, D.A. et.al., “Thrombus Imaging Using Technetium-99M-Labeled High Potency GPIIB/IIIA Receptor Antagonists. Chemistry and Initial Biological Studies” Journal of Medicinal Chemistry, American Chemical society, Washington, US, vol. 39, No. 7, 1996 pp. 1372-1382.
Harris, T.D., et.al., “Tc-99m-labeled Fibrinogen Receptor Antagonists: Design and Synthesis of Cyclic RGD Peptides for the Detection of Thrombi” Bioorganic & Medicinal Chemistry Letters, Oxford, GB, vol. 6, No. 15, Aug. 1996 pp. 1741-1746.
Cuthbertson Alan
Solbakken Magne
Audet Maury
Bohlken Craig
GE Healthcare AS
LandOfFree
Imaging agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Imaging agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imaging agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4158882